CAMP

CAMP4 Therapeutics Corp

Add to Watchlist

Advanced Chart

1.740

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.740

Open

1.740

VWAP

Vol

6.55K

Mkt Cap

660.34K

Low

1.740

Amount

EV/EBITDA(TTM)

Total Shares

1.65M

-21.11M

EV/OCF(TTM)

P/S(TTM)

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2024Q4

57.00M

-27.75%

-1.610

-1420.75%

54.00M

-23.83%

-2.070

-250%

Estimates Revision

The market is revising No Change the revenue expectations for CalAmp Corp. (CAMP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -0.57%.

Revenue Estimates for FY2024

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2024

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-0.57%

In Past 3 Month

5 Analyst Rating

776.44% Upside

Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

776.44% Upside

Current: 1.740

Low

8.00

Averages

15.25

High

18.00

776.44% Upside

Current: 1.740

Low

8.00

Averages

15.25

High

18.00

Wedbush

NULL -> Outperform

initiated

2025-05-27

Reason

Wedbush

Price Target

2025-05-27

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target.

Wedbush

Yun Zhong

Outperform

initiated

2025-05-27

Reason

Wedbush

Yun Zhong

Price Target

2025-05-27

initiated

Outperform

Reason

Wedbush analyst Yun Zhong initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target. The company's lead candidate CMP-CPS-01 increases the expression of an enzyme for the treatment of urea cycle disorders that affect approximately 20,000 U.S. and European Union patients with no disease modifying treatments available, the analyst tells investors in a research note. The firm says preclinical data show efficient and sustained reduction of ammonia, the root cause of all disease symptoms, and increased expression of additional urea cycle enzymes as well, suggesting approximately 90% of urea cycle disorders patients will be eligible for treatment. Wedbush's calculation suggests approximately 2,000 such patients in the U.S., indicating a $1B opportunity.

Piper Sandler

Edward Tenthoff

Buy

Initiates

$18

2024-11-05

Reason

Piper Sandler

Edward Tenthoff

Price Target

$18

2024-11-05

Initiates

Buy

Reason

Piper Sandler initiated coverage of Camp4 Therapeutics with an Overweight rating and $18 price target. The company is is pioneering development of regulatory RNAs as a novel therapeutic modality, the analyst tells investors in a research note. The firm estimates Camp4 holds pro forma cash of $79M to fund operations into Q2 of 2026.

JP Morgan

Eric Joseph

Buy

Initiates

$23

2024-11-05

Reason

JP Morgan

Eric Joseph

Price Target

$23

2024-11-05

Initiates

Buy

Reason

JPMorgan initiated coverage of Camp4 Therapeutics with an Overweight rating and $23 price target. The firm says its bullish thesis is based on Camp4's ASO RNA Actuator Platform, which it believes offers the potential to systematically restore the expression of specific proteins as a means of modifying disorders due to genetic haploinsufficiency. It sees the shares becoming constructive with potentially de-risking clinical readouts in Q1 and the second half of 2025.

Leerink Partners

Mani Foroohar

Buy

Initiates

$17

2024-11-05

Reason

Leerink Partners

Mani Foroohar

Price Target

$17

2024-11-05

Initiates

Buy

Reason

Leerink initiated coverage of Camp4 Therapeutics with an Outperform rating and $17 price target. The firm believes CMP-CPS-001, the lead program in urea cycle disorders, offers a pathway to differentiation in a well-defined total addressable population, good product/market fit with Camp4's regRNA-targeting ASO approach, and a steady cadence of data catalysts to clarify the asset's clinical profile in the time horizon contemplated by its rating. Beyond CMP-CPS-001, Leerink sees potential BD/licensing of Camp4's RAP platform and further pipeline development as a source of unmodeled upside to its projections.

William Blair

Myles Minter

Buy

Initiates

n/a

2024-11-05

Reason

William Blair

Myles Minter

Price Target

n/a

2024-11-05

Initiates

Buy

Reason

William Blair initiated coverage of Camp4 Therapeutics with an Outperform rating.

See All Ratings

Valuation Metrics

The current forward P/E ratio for CAMP4 Therapeutics Corp (CAMP.O) is 0.04, compared to its 5-year average forward P/E of 9.40. For a more detailed relative valuation and DCF analysis to assess CAMP4 Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

9.40

Current PE

0.04

Overvalued PE

147.33

Undervalued PE

-128.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

15.56

Current EV/EBITDA

8.16

Overvalued EV/EBITDA

20.32

Undervalued EV/EBITDA

10.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.63

Current PS

0.00

Overvalued PS

1.10

Undervalued PS

0.17

Financials

Annual

Quarterly

FY2025Q1

YoY :

-98.79%

858.00K

Total Revenue

FY2025Q1

YoY :

+450.42%

-13.10M

Operating Profit

FY2025Q1

YoY :

+208.36%

-12.43M

Net Income after Tax

FY2025Q1

YoY :

+463.64%

-0.62

EPS - Diluted

FY2025Q1

YoY :

+194.96%

-14.57M

Free Cash Flow

FY2025Q1

YoY :

+174.35%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

YoY :

+25366.96%

-1.45K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

71.4M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

2.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

71.4M

USD

Months

CAMP News & Events

Events Timeline

2025-05-16 (ET)

2025-05-16

06:06:04

Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders

2025-05-13 (ET)

2025-05-13

16:11:56

Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)

2025-03-18 (ET)

2025-03-18

08:13:58

Camp4 Therapeutics appoints Williams, Stewart to board of directors

News

4.0

05-27Benzinga

This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

9.5

05-13Newsfilter

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

2.0

05-06Benzinga

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

People Also Watch

IROH

Iron Horse Acquisitions Corp

Black Hawk Acquisition Corp

Oramed Pharmaceuticals Inc

Milestone Scientific Inc

ALX Oncology Holdings Inc

Assembly Biosciences Inc

Coda Octopus Group Inc

7.650

USD

0.00%

FAQ

What is CAMP4 Therapeutics Corp (CAMP) stock price today?

The current price of CAMP is 1.74 USD — it has increased 0 % in the last trading day.

CAMP

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CAMP News & Events

Events Timeline

News

People Also Watch

FAQ

What is CAMP4 Therapeutics Corp (CAMP) stock price today?

What is CAMP4 Therapeutics Corp (CAMP)'s business?

What is the price predicton of CAMP Stock?

What is CAMP4 Therapeutics Corp (CAMP)'s revenue for the last quarter?

What is CAMP4 Therapeutics Corp (CAMP)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for CAMP4 Therapeutics Corp (CAMP)'s fundamentals?

How many employees does CAMP4 Therapeutics Corp (CAMP). have?

What is CAMP4 Therapeutics Corp (CAMP) market cap?